Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31394337 | 0.86 | NPC1 (0.33) | TAAR1DGAT1GPR17MAPT | |
| SCHEMBL1772195 | 0.86 | TAAR1 (0.34) | TAAR1DGAT1GPR17DRD4AKR1B1 | |
| SCHEMBL29673284 | 0.84 | — | — | |
| SCHEMBL21682051 | 0.84 | DGAT1 (0.33) | TAAR1DGAT1 | |
| SCHEMBL29546230 | 0.84 | HTR1D (0.35) | MAPT | |
| SCHEMBL23287117 | 0.84 | NMT1 (0.32) | TAAR1MAPT | |
| SCHEMBL18381121 | 0.84 | — | — | |
| SCHEMBL17419026 | 0.84 | HTR1D (0.35) | MAPT | |
| SCHEMBL14485312 | 0.81 | ACVRL1 (0.33) | DGAT1GPR17TSHRMAPT | |
| SCHEMBL16266320 | 0.80 | DGAT1 (0.32) | TAAR1DGAT1GPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER, INC. | 2001-09-06 | — | — | US | claimed |
| EP-1084114-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| WO-1999062890-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | claimed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12595230-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-07 | — | — | US | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12479853-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3909949-B1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025096495-A1 | ARYL FLUOROSULFATE-BASED INHIBITORS AS NOVEL ANTITUBERCULAR AGENTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| EP-1084114-B1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6548526-B2 | Isothiazole derivatives useful as anticancer agents | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER, INC. | 2001-09-06 | — | — | US | disclosed |
| US-6235764-B1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
| EP-1084114-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062890-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | ESRRA, FSHR, GPER1 | TAAR1 819/4885DGAT1 3817/4885GPR17 448/4885 |
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | TP53, MCL1, ACIN1 | TAAR1 4466/4885DGAT1 2863/4885GPR17 3152/4885 |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TAAR1 599/4885DGAT1 355/4885GPR17 150/4885 |
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | TP53, MCL1, ACIN1 | TAAR1 4466/4885DGAT1 2863/4885GPR17 3152/4885 |
| US-12479853-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | TAAR1 4232/4885DGAT1 2661/4885GPR17 2683/4885 |
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | CYP3A5, CYP3A7, CYP3A43 | TAAR1 3654/4885DGAT1 1857/4885GPR17 995/4885 |
| US-12595230-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | FSHR, CYP19A1, GPER1 | TAAR1 620/4885DGAT1 3311/4885GPR17 772/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | TAAR1 3244/4885DGAT1 4614/4885GPR17 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.